May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
The Antimicrobial Activity of Gatifloxcin (GAT) With or Without Benzalkonium Chloride (BAK) Against Ocular Bacterial Pathogens
Author Affiliations & Notes
  • J.M. Blondeau
    Clinical Microbiology, Royal Univ Hosp, Saskatoon, SK, Canada
  • P. Hedlin
    Clinical Microbiology, Royal Univ Hosp, Saskatoon, SK, Canada
    University of Saskatchewan, Saskatoon, SK, Canada
  • S.D. Borsos
    Clinical Microbiology, Royal Univ Hosp, Saskatoon, SK, Canada
  • Footnotes
    Commercial Relationships  J.M. Blondeau, Allergan F; P. Hedlin, None; S.D. Borsos, None.
  • Footnotes
    Support  Allergan
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 4880. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J.M. Blondeau, P. Hedlin, S.D. Borsos; The Antimicrobial Activity of Gatifloxcin (GAT) With or Without Benzalkonium Chloride (BAK) Against Ocular Bacterial Pathogens . Invest. Ophthalmol. Vis. Sci. 2005;46(13):4880.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To compare gatifloxacin with and without benzalkonium chloride (BAK) against several ocular pathogens. Methods: Ocular and American Type Culture Collection (ATCC) control strains of Haemophilus influenzae (HI), Streptococcus pneumoniae (SP), Staphylococcus aureus (SA), Pseudomonas aeruginosa (PA) and E. coli (EC) were tested by microbroth dilution against GAT with or without BAK according to the guidelines recommended by the National Committee for Clinical Laboratory Standards (NCCLS) using Mueller–Hinton or Todd–Hewitt broth. Inoculated plates were incubated in ambient atmosphere for 18–20 hours at 35°C and the lowest concentration showing no growth was the MIC. Results: Varying concentrations of BAK were either held constantly or serially diluted along with GAT. MICs (µg/ml) for GAT alone versus with BAK against ATCC strains were as follows for the various organisms tested: SP 0.25 vs <0.001; HI 0.016 vs 0.004–0.008; PA 0.5 vs <0.004; EC <0.004 vs <0.004; SA 0.031–0.063 vs 0.004; For GAT vs GAT with BAK, MICs (µg/ml) against clinical ocular isolates were as follows: SP 0.25–0.5 vs <0.001; HI 0.008–0.016 vs 0.004–0.008. For clinical strains, 83% had at least 1 doubling dilution drop in the MIC in the presence of BAK as compared to SP where 100% of strains had a >7 doubling dilution decline in MICs. Conclusions: The presence of varying concentrations of BAK with GAT resulted in a reduction in MICs of both control strains and clinically ocular bacterial pathogens . BAK has an additive effect when used with GAT in reducing bacterial MICs and this observation may have important clinical implications.

Keywords: antibiotics/antifungals/antiparasitics • bacterial disease • microbial pathogenesis: experimental studies 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×